Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009044 · ClinicalTrials.gov registry record · Phase 2
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
A Phase 2 study of Invasive Breast Carcinoma and Cancer Survivor, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 2
- Study locations
NCT04009044 is a Phase 2 study of Invasive Breast Carcinoma and Cancer Survivor that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 156 participants, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04009044, a Phase 2 study of Invasive Breast Carcinoma and Cancer Survivor, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well topical afimoxifene works in treating patients with breast cancer who have undergone radiation therapy on one breast. Topical afimoxifene is a quick-drying medicated gel that may block the growth of breast cancer cells when applied to the breast skin. The purpose of this research is to determine what effect, if any, differences in skin type between women have on the delivery of topical afimoxifene to the breast tissue, and whether radiation affects the delivery of topical afimoxifene to breast tissue.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- PROCEDURE Core Biopsy
- DRUG Afimoxifene
Study Locations (2)
Illinois
- Northwestern University - Chicago
- University of Illinois Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2026-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04009044
The ClinicalTrials.gov registry entry for NCT04009044 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (68% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04009044 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04009044 about?
NCT04009044 is a clinical study titled "Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast". This phase II trial studies how well topical afimoxifene works in treating patients with breast cancer who have undergone radiation therapy on one breast. Topical afimoxifene is a quick-drying medicated gel that may block the growth of breast cancer cells when applied to the breast skin. The purpose...
What is the current status of trial NCT04009044?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2020-02-17. Estimated completion is 2026-06-25.
What conditions does trial NCT04009044 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Cancer Survivor, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT04009044?
The interventions under investigation include: Questionnaire Administration (OTHER), Core Biopsy (PROCEDURE), Afimoxifene (DRUG).
Who is sponsoring clinical trial NCT04009044?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04009044 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.